Search clinical trials for: Fluad, MF59, Fluzone, HDFlu, Influenza, Vaccine

Total 9946 results

Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Seqirus

Completed

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Influenza

Finland, Philippines, Thailand
Seqirus
Department of Health and Human Services

Recruiting

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

Philippines, United States
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Seqirus

Completed

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza | Human

United States
Seqirus

Completed

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

United States, Estonia, Germany
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Pandemic | Avian Influenza

Colombia
HIV Vaccine Trials Network
South Africa AIDS Vaccine Initiative

Completed

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

HIV Seronegativity | HIV Preventive Vaccine

South Africa
Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

Influenza

United States, Mexico
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
Mayo Clinic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Gene Signatures of Influenza Vaccine Responses in Older Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Influenza | Healthy Volunteers

United States
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
Seqirus

Active, not recruiting

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Influenza, Human

Philippines, United States, Germany, Pakistan, Canada, Estonia, Denmark, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy | HIV Seronegativity
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

Influenza

United States, Mexico
Novartis Vaccines
Novartis

Completed

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

Influenza

United States, Mexico
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

Novel 2009 Influenza H1N1

Costa Rica
Chiron Corporation

Completed

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

HIV Infections | HIV Seronegativity

United States
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Seqirus

Completed

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Infections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza, Human | Orthomyxoviridae Infections | Influenza in Birds

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Icosavax, Inc.

Completed

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Healthy

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

HIV Infections

United States
Novartis Pharmaceuticals

Completed

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Alzheimer's Disease

Belgium, Switzerland, Spain, United States, Italy, Sweden, Canada, Germany, Norway, Netherlands
Tel-Aviv Sourasky Medical Center

Unknown

Vaccination Against Influenza H1N1 in Rheumatic Diseases

Rheumatic Diseases | Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

HIV Infections

United States
Tel-Aviv Sourasky Medical Center

Unknown

Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics

Influenza H1N1
HepNet Study House, German Liverfoundation

Terminated

H1N1sw Vaccine in Adult Transplant Recipients

Immunocompromised

Germany
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
Seqirus
Biomedical Advanced Research and Development Authority

Completed

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

Influenza | Avian Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
National Institute of Allergy and Infectious Diseases...

Completed

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

HIV Infections

United States
Robert Pass, MD
National Institute of Allergy and Infectious Diseases (NIAID); MCM Vaccines...

Completed

Recombinant CMV gB Vaccine in Postpartum Women

Cytomegalovirus Infections

United States
Biomedical Advanced Research and Development Authority
Rho, Inc.

Completed

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Influenza, Human

United States
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States

3

Subscribe